PS-341–mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis

This publication has 53 references indexed in Scilit:

• Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
  Blood, 2004
• The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2004
• Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors
  Clinical Cancer Research, 2004
• Cancer Statistics, 2004
  CA: A Cancer Journal for Clinicians, 2004
• A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
  Bone Marrow Transplantation, 2003
• Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation
  Oncogene, 2003
• The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
  Blood, 2003
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
  Blood, 2003
• Inhibition of Nuclear Factor-κB Activity Is Involved in E1A-mediated Sensitization of Radiation-induced Apoptosis
  Published by Elsevier ,1997
• p53 is required for radiation-induced apoptosis in mouse thymocytes
  Nature, 1993